Show simple item record

dc.contributor.authorWhitehead, E
dc.contributor.authorShalet, Stephen M
dc.contributor.authorBlackledge, G
dc.contributor.authorTodd, Ian D
dc.contributor.authorCrowther, Derek
dc.contributor.authorBeardwell, Colin G
dc.date.accessioned2014-12-09T12:12:25Z
dc.date.available2014-12-09T12:12:25Z
dc.date.issued1983-09-15
dc.identifier.citationThe effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. 1983, 52 (6):988-93 Canceren
dc.identifier.issn0008-543X
dc.identifier.pmid6411321
dc.identifier.urihttp://hdl.handle.net/10541/336983
dc.description.abstractOvarian function has been studied in 44 adult females who previously received quadruple chemotherapy (MVPP) for Hodgkin's disease. The median age at treatment was 23 years, and the length of time between completion of treatment and study ranged from 6 months to 10 years (median, 30 months). Seventeen women maintained regular menses, 10 developed oligomenorrhea, and 17 developed amenorrhea. At treatment, the 17 women who subsequently developed amenorrhea were significantly older (median, 30 years) than those who maintained regular menses (median, 22 years) or developed oligomenorrhea (median, 23 years). All patients older than 36 years at the start of treatment stopped menstruating during chemotherapy. The cause of the menstrual disturbance in these patients was chemotherapy-induced ovarian damage characterized by high serum gonadotrophin and low serum estradiol concentrations. After completion of treatment there were 17 pregnancies, which resulted in 9 normal infants, 3 terminations, and 4 spontaneous abortions. Nine patients took the combination oral contraceptive pill throughout chemotherapy; however, subsequently 4 developed amenorrhea and 3 oligomenorrhea, suggesting that these patients had not been protected from chemotherapy-induced ovarian damage. Estrogen replacement therapy was of definite benefit in the symptomatic patients with premature ovarian failure.
dc.language.isoenen
dc.rightsArchived with thanks to Canceren
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAntineoplastic Agents
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshChorionic Gonadotropin
dc.subject.meshDrug Therapy, Combination
dc.subject.meshEstradiol
dc.subject.meshFemale
dc.subject.meshFollicle Stimulating Hormone
dc.subject.meshHodgkin Disease
dc.subject.meshHumans
dc.subject.meshMechlorethamine
dc.subject.meshMenstruation Disturbances
dc.subject.meshMiddle Aged
dc.subject.meshOvary
dc.subject.meshPrednisolone
dc.subject.meshProcarbazine
dc.subject.meshRetrospective Studies
dc.subject.meshVinblastine
dc.titleThe effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital and Holt Radium Institute, Wilmslow Rd, Manchester.en
dc.identifier.journalCanceren
html.description.abstractOvarian function has been studied in 44 adult females who previously received quadruple chemotherapy (MVPP) for Hodgkin's disease. The median age at treatment was 23 years, and the length of time between completion of treatment and study ranged from 6 months to 10 years (median, 30 months). Seventeen women maintained regular menses, 10 developed oligomenorrhea, and 17 developed amenorrhea. At treatment, the 17 women who subsequently developed amenorrhea were significantly older (median, 30 years) than those who maintained regular menses (median, 22 years) or developed oligomenorrhea (median, 23 years). All patients older than 36 years at the start of treatment stopped menstruating during chemotherapy. The cause of the menstrual disturbance in these patients was chemotherapy-induced ovarian damage characterized by high serum gonadotrophin and low serum estradiol concentrations. After completion of treatment there were 17 pregnancies, which resulted in 9 normal infants, 3 terminations, and 4 spontaneous abortions. Nine patients took the combination oral contraceptive pill throughout chemotherapy; however, subsequently 4 developed amenorrhea and 3 oligomenorrhea, suggesting that these patients had not been protected from chemotherapy-induced ovarian damage. Estrogen replacement therapy was of definite benefit in the symptomatic patients with premature ovarian failure.


This item appears in the following Collection(s)

Show simple item record